Mylab partners with Serum India’s CEO Adar Poonawalla and Abhijit Pawar to scale-up production of Covid-19 test kits
In order to scale up the operations and escalate faster delivery of testing kits for the novel coronavirus (Covid-19), Pune-based molecular diagnostics company Mylab Discovery Solutions Pvt Ltd has partnered with Serum India’s CEO Adar
In order to scale up the operations and escalate faster delivery of testing kits for the novel coronavirus (Covid-19), Pune-based molecular diagnostics company Mylab Discovery Solutions Pvt Ltd has partnered with Serum India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG. Funds invested will be used for scaling production of COVID-19 testing kits and expansion of molecular diagnostic solutions.
“We are honoured to stand by our Prime Minister and our government, while supporting them during these trying times. This partnership will ensure we do our bit to help in this time of crisis.“ said Abhijit Pawar, Chairman AP Globale, MD – Sakal Media Group
Talking about the partnership, Serum Institute India’s CEO Adar Poonawalla said, “In the next few weeks we will be ramping up the production of the Covid-19 testing kits taking from 1.5 lakh tests/week to 20 lakh tests/week. The shortage of testing kits will come to an end in a month or two”.
“This partnership can Impact Billions of people across the world ,especially India“, said Hasmukh Rawal, MD, Mylab Discovery Solutions. Mylab is the first Indian company to get commercial approval for its testing kits named as Mylab PathoDetect COVID-19 Qualitative PCR kit. The testing kit is approved by Indian FDA/ Central Drugs Standard Control Organisation (CDSCO) and ICMR evaluation. “This will help Mylabs create a world class organization, which will help India become a leader in molecular diagnostics’’, noted Sujit Jain, Director ,Mylab Discovery solutions Pvt ltd, MD Netsurf
“Global innovation is the need of the hour to curb this pandemic that has affected millions across the world. The need for the maintenance and manufacturing of medical and healthcare equipment at the pace required to keep the numbers at bay has never been more important. Mylabs and their team have shown exceptionally innovative capabilities when they were able to develop a time-saving testing kit within 6-weeks of its outbreak. Keeping in mind their resilient approach and quick response, I am certain that the company has a variety of similar innovation-driven projects which will help bring drastic improvements in the healthcare sector. The investment towards Mylab will enable them to build their infrastructure and expand their capabilities further.”, said Adar Poonawalla, CEO, Serum Institute of India
The Mylab manufacturing facility, approved by FDA/CDSCO is compliant with MDR 2017 regulation for Manufacturing Medical Device of Class A,B,C and D and ISO 13485: 2016 certification. The legal advisory for this partnership was led by Hitesh Jain, Managing Partner, Parinam Law Associates.